My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

793.97 -2.58 (-0.32%)

Streaming Delayed Price Updated: 9:34 AM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

58 59 Next >

Insights into Regeneron Pharmaceuticals's Upcoming Earnings ↗

April 28, 2025

Via Benzinga

Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment. ↗

April 28, 2025

A fundamental analysis of (NASDAQ:REGN): Should Quality Investors Include NASDAQ:REGN in Their Portfolio?

Via Chartmill

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

April 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

April 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron (REGN) Reports Earnings Tomorrow: What To Expect

April 28, 2025

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

Via StockStory

Topics World Trade

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold ↗

April 26, 2025

Via The Motley Fool

Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal ↗

April 22, 2025

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and long-term production.

Via Benzinga

Regeneron Inks Deal With Fujifilm Diosynth Biotechnologies To Increase Manufacturing In US: Retail’s Optimistic ↗

April 22, 2025

The agreement is to manufacture and supply bulk drug products of Regeneron’s commercial biologic medicines at Fujifilm’s Holly Springs, North Carolina, campus for a period of 10 years.

Via Stocktwits

Topics Economy Stocks

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

April 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

April 21, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Discover which S&P500 stocks are making waves on Monday. ↗

April 21, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

April 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

April 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion ↗

April 17, 2025

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Via Benzinga

Assessing Regeneron Pharmaceuticals: Insights From 7 Financial Analysts ↗

April 17, 2025

Via Benzinga

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

April 17, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗

April 16, 2025

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating...

Via Benzinga

Topics Government

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study ↗

April 15, 2025

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Via Benzinga

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

April 15, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

April 14, 2025

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

These S&P500 stocks are gapping in today's session ↗

April 09, 2025

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

Via Chartmill

Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗

April 09, 2025

Via Benzinga

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗

April 07, 2025

Via The Motley Fool

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

April 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst...

Via StockStory

Topics Artificial Intelligence

3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years ↗

April 05, 2025

Via The Motley Fool

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗

April 04, 2025

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Via Benzinga

Topics Government World Trade

In a market where value is scarce, REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers a refreshing opportunity with its solid fundamentals. ↗

April 02, 2025

Uncover the potential of REGENERON PHARMACEUTICALS, an undervalued stock. NASDAQ:REGN maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗

April 02, 2025

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

Via Stocktwits

Topics ETFs Government

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.